Grant Award Details
A cellular immunotherapy approach (candidate) that targets non-small cell lung carcinoma (NSCLC) with EGFR mutations, and colorectal cancer (CRC) with KRAS mutations.
Grant Application Details
- Novel Rejuvenated T Cell Immunotherapy for Lung Cancer
Through this project, we would like to evaluate how this T-iPSC-based immunotherapy that we have developed can eliminate lung cancer cells effectively in vivo using xenografted SCID mice.
This novel T-iPSC-based immunotherapy will provide another effective treatment for lung cancer and possible other malignancies by supplying unlimited number of young and active CTLs.
Major Proposed Activities
- Peptides synthesis for EGFR mutation hot spots and selection of the peptides with affinity binding assay
- Patient lung cancer/ blood cell culture and xenograft establishment in SCID mice for establishing tumor model
- Peptide responsive T cell selection, IPS induction and T cell redifferentiation and expansion (rejCTL) for cell-based immunotherapy
- transfusion of patient specific rejCTL cells into lung cancer grafted mice to treat tumors
- Evaluation of the efficacy of rejCTL cell therapy by observing tumor sizes in xenografted mice
- Statistical analysis and conclusion for this novel cell-based cancer treatment and contact FDA for initiation of a clinical trial
Lung cancer is known to cause the highest fatality rate. California State and citizens suffer similarly as the US and worldwide do. A fairly common HLA allele, e.g. HLA A0201 presents in up to 50% of California populations. Thus, we can provide an ‘off the shelf’ therapy for most of cancer patients. As a California based institute, we will succeed this research and pioneer this frontier cell- based immunotherapy, and conduct a possible clinical trial through CIRM funding.